National Institute on Aging; Amended Notice of Meeting, 68547 [2015-28230]
Download as PDF
Federal Register / Vol. 80, No. 214 / Thursday, November 5, 2015 / Notices
III. Electronic Access
Persons with access to the Internet
may obtain the document at either
https://www.fda.gov/ScienceResearch/
SpecialTopics/RunningClinicalTrials/
ProposedRegulationsand
DraftGuidances/default.htm, or https://
www.hhs.gov/ohrp/newsroom/
index.html, or https://
www.regulations.gov.
Dated: October 23, 2015.
Karen B. DeSalvo,
Acting Assistant Secretary for Health. U.S.
Department of Health and Human Services.
Dated: October 27, 2015.
Leslie Kux,
Assistant Commissioner for Policy, U.S. Food
and Drug Administration.
[FR Doc. 2015–27986 Filed 11–4–15; 8:45 am]
BILLING CODE 4164–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Amended
Notice of Meeting
Notice is hereby given of a change in
the meeting of the National Institute on
Aging Special Emphasis Panel,
November 12, 2015, 10:00 a.m. to
November 12, 2015, 02:00 p.m.,
National Institute on Aging, Gateway
Building, 7201 Wisconsin Avenue, Suite
2C212, Bethesda, MD, 20892 which was
published in the Federal Register on
October 19, 2015, 80 FR 63236.
The meeting notice is amended to
change the date of the meeting from
November 12, 2015 to November 24,
2015. The meeting is closed to the
public.
Dated: October 30, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–28230 Filed 11–4–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
jstallworth on DSK7TPTVN1PROD with NOTICES
National Institutes of Health
Prospective Grant of Exclusive
License: Development of Therapeutics
To Treat Brain Injury and
Neurodegenerative Disease
National Institute of Diabetes
and Digestive and Kidney Diseases,
National Institutes of Health, Public
Health Service, DHHS.
ACTION: Notice.
AGENCY:
VerDate Sep<11>2014
15:06 Nov 04, 2015
Jkt 238001
This notice, in accordance
with 35 U.S.C. 209(c)(1) and 37 CFR
part 404.7, that the National Institute of
Diabetes and Digestive and Kidney
Diseases, National Institutes of Health,
Department of Health and Human
Services, is contemplating the grant of
an exclusive patent license to Astrocyte
Pharmaceuticals, Inc., (‘‘Astrocyte’’), a
company incorporated under the laws of
Delaware and having an office in
Cambridge, Massachusetts, to practice
the following inventions embodied in
the following patent applications: US
Provisional Patent Appl. No. 60/176,373
entitled, ‘‘Methanocarba cycloalkyl
nucleoside analogues,’’ filed 14 Jan 2000
[HHS reference E–176–1999/0–US–01];
Intl. Appl. No. PCT/US01/00981,
entitled, ‘‘Methanocarba cycloalkyl
nucleoside analogues,’’ filed 12 Jan 2001
[HHS reference E–176–1999/0–PCT–02];
Australia Patent No. 2001230913, issued
13 Oct 2005 [HHS reference E–176–
1999/0–AU–03]; Canada Patent No.
2.397,366, issued 15 Mar 2011 [HHS
reference E–176–1999/0–CA–04];
European Patent Appl. No. 01903043.6
entitled, filed 12 Jan 2001 [HHS Ref No
E–176–1999/0–EP–05]; US Patent No.
7,087,589, issued 8 Aug 2006 [HHS
reference E–176–1999/0–US–06]; US
patent No. 7,790,735, issued 8 Aug 2006
[HHS reference E–176–1999/0–US–07];
and Great Britain patent No. 1252160,
issued 16 Aug 2006 [HHS reference E–
176–1999/0–US–08]. The patent rights
in these inventions have been assigned
to the United States of America. The
territories included in this license may
be worldwide. The field of use may be
related to ‘‘Use of the patent rights in
the development and sale of
therapeutics for cerebral trauma, stroke,
and neurodegenerative disorders.’’
DATES: Only written comments or
applications for a license (or both)
which are received by the Technology
Advancement Office of the National
Institute of Diabetes and Digestive and
Kidney Diseases (NIDDK) on or before
November 20, 2015 will be considered.
ADDRESSES: Requests for copies of the
patent application, patents, inquiries,
comments, and other materials relating
to the contemplated exclusive license
should be directed to: Patrick McCue,
Ph.D., Senior Licensing and Patenting
Manager, Technology Advancement
Office, The National Institute of
Diabetes and Digestive and Kidney
Diseases, 12A South Drive, Bethesda,
MD 20892, Telephone: (301) 435–5560;
Email: patrick.mccue@nih.gov. A signed
confidentiality non-disclosure
agreement will be required to receive
copies of any patent applications that
have not been published by the United
SUMMARY:
PO 00000
Frm 00056
Fmt 4703
Sfmt 4703
68547
States Patent and Trademark Office or
the World Intellectual Property
Organization.
SUPPLEMENTARY INFORMATION:
The technology provides novel
nucleoside and nucleotide derivatives
that are agonist or antagonists of P1 and
P2 receptors and may be useful in the
treatment or prevention of various
diseases including airway diseases,
cancer, cardiac arrhythmias, cardiac
ischemia, epilepsy, and Huntington’s
Disease.
The prospective exclusive license will
be royalty bearing and will comply with
the terms and conditions of 35 U.S.C.
209 and 37 CFR part 404. The
prospective exclusive license may be
granted unless within fifteen (15) days
from the date of this published notice,
the NIDDK receives written evidence
and argument that establishes that the
grant of the license would not be
consistent with the requirements of 35
U.S.C. 209 and 37 CFR part 404.
Properly filed competing applications
for a license received by the NIDDK in
response to this notice will be treated as
objections to the contemplated license.
Comments and objections submitted in
response to this notice will not be made
available for public inspection and, to
the extent permitted by law, will not be
released under the Freedom of
Information Act, 5 U.S.C. 552.
Dated: October 30, 2015.
Anna Z. Amar,
Acting Deputy Director, Technology
Advancement Office, National Institute of
Diabetes and Digestive and Kidney Diseases,
National Institutes of Health.
[FR Doc. 2015–28245 Filed 11–4–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Cancer Institute; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
E:\FR\FM\05NON1.SGM
05NON1
Agencies
[Federal Register Volume 80, Number 214 (Thursday, November 5, 2015)]
[Notices]
[Page 68547]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-28230]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Aging; Amended Notice of Meeting
Notice is hereby given of a change in the meeting of the National
Institute on Aging Special Emphasis Panel, November 12, 2015, 10:00
a.m. to November 12, 2015, 02:00 p.m., National Institute on Aging,
Gateway Building, 7201 Wisconsin Avenue, Suite 2C212, Bethesda, MD,
20892 which was published in the Federal Register on October 19, 2015,
80 FR 63236.
The meeting notice is amended to change the date of the meeting
from November 12, 2015 to November 24, 2015. The meeting is closed to
the public.
Dated: October 30, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2015-28230 Filed 11-4-15; 8:45 am]
BILLING CODE 4140-01-P